acquired
Stage
About
Dezima develops small molecule therapies for the treatment of dyslipidemia and was acquired by Amgen.
Explore Dezima's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.
Dezima develops small molecule therapies for the treatment of dyslipidemia and was acquired by Amgen.
Funding rounds, investor list, and risk signals — unlock with a subscription.